Bombardier Announces Pricing of its New Issuance of Senior Notes due 2030
MONTRÉAL, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has successfully priced its offering of US$750 million aggregate principal amount of new Senior Notes due November 15, 2030. The new Senior Notes will carry a coupon of 8.750% per annum and will be sold at par (the “New Notes”). The issuance of the New Notes is expected to close on or about November 17, 2023, subject to customary closing conditions.
Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to fund the redemption (the “2025 Notes Redemption”) of all of its outstanding 7.50% Senior Notes due 2025 (the “2025 Notes”), of which there is $380 million aggregate principal amount outstanding on the date hereof, (ii) to finance the offers to purchase (the “2026-2027 Tender Offer”) up to $360 million aggregate purchase amount (exclusive of accrued and unpaid interest) of its outstanding 7.125% Senior Notes due 2026 (the “2026 Notes”) and 7.875% Senior Notes due 2027 (the “2027 Notes”), of which there is $1,200 million aggregate principal amount outstanding of the 2026 Notes and $1,892 million aggregate principal amount outstanding of the 2027 Notes on the date hereof, and/or for the repayment of other indebtedness, and (iii) for the payment of accrued interest and related fees and expenses.
Consummation of the offering of the New Notes, the 2025 Notes Redemption and the 2026-2027 Tender Offer are subject to market and other conditions, and there can be no assurance that Bombardier will be able to successfully complete these transactions on the terms described above, or at all. The 2025 Notes Redemption and the 2026-2027 Tender Offer are subject to certain conditions, including the completion of the offering of the New Notes prior to December 6, 2023, as it relates to the 2025 Notes Redemption, and prior to November 24, 2023, as it relates to the 2026-2027 Tender Offer.
This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful.
The New Notes mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. The New Notes mentioned herein may be offered and sold in the United States only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the U.S. Securities Act and outside the United States in reliance on Regulation S under the U.S. Securities Act. The New Notes mentioned herein have not been and will not be qualified for distribution to the public under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. The New Notes will be offered and sold in Canada on a private placement basis only to “accredited investors” pursuant to certain prospectus exemptions.
This announcement does not constitute an offer to purchase or the solicitation of an offer to sell the New Notes, the 2025 Notes, the 2026 Notes or the 2027 Notes. This announcement does not constitute a redemption notice in respect of any 2025 Notes or any other notes. Any redemption of the 2025 Notes or any other notes will be made pursuant to a notice of redemption under the indentures governing such notes. Any purchase of the 2026 Notes or 2027 Notes pursuant to the 2026-2027 Tender Offer will be made pursuant to an offer to purchase.
Certain statements in this announcement are forward-looking statements based on current expectations. By their nature, forward-looking statements require us to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from those set forth in the forward-looking statements.
|Francis Richer de La Flèche|
Vice President, Financial Planning and Investor Relations Bombardier
+1 514 240 9649
Senior Director, Communications
+1 514 855 7167
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Avance Gas Holding Ltd: Ex Dividend USD 0.50 today7.12.2023 07:01:00 CET | Press release
Hamilton, Bermuda, December 7, 2023 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.50 as of today relating to the dividend for the third quarter of 2023. The dividend will be paid on December 15, 2023. For further information, please contact: Randi Navdal Bekkelund - Chief Financial Officer Tel: +47 23 11 40 00 Email: IR@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and operates a fleet of fourteen modern ships including two dual fuel LPG newbuildings for delivery in early 2024 as well as four medium sized gas/ammonia carriers due for delivery in 2025 and 2026. For more information about Avance Gas, please visit www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook7.12.2023 07:00:00 CET | Press release
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results. Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and road
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC7.12.2023 07:00:00 CET | Press release
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade. The target FDA PDUFA date under priority review is June 10, 2024. The European Medicines Agency (EMA) has also validated Ipsen’s Marketing Authorization Applica
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage7.12.2023 07:00:00 CET | Press release
Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission. In a staged roll-out across the key European markets, launches will follow in the UK and France later that year, with Spain and Italy scheduled to launch in early 2025,” said Dario Eklund, CEO of Santhera. “With Geert Jan and Marc joining the Executive Committee, we are leveraging the existing expertise within our leadership team and are elevating the commercial and supply chain functions to their level of importance as we enter the commercial market.” Geert Jan van Daal, MD, PhD, has held v
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology7.12.2023 03:30:00 CET | Press release
R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapiesEnhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 yearsAmbition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of